Abacavir, an anti-HIV-1 drug, targets TDP1-deficient adult T cell leukemia

阿巴卡韦是一种抗 HIV-1 药物,靶向治疗缺乏 TDP1 的成人 T 细胞白血病

阅读:9
作者:Kohei Tada, Masayuki Kobayashi, Yoko Takiuchi, Fumie Iwai, Takashi Sakamoto, Kayoko Nagata, Masanobu Shinohara, Katsuhiro Io, Kotaro Shirakawa, Masakatsu Hishizawa, Keisuke Shindo, Norimitsu Kadowaki, Kouji Hirota, Junpei Yamamoto, Shigenori Iwai, Hiroyuki Sasanuma, Shunichi Takeda, Akifumi Takaori-

Abstract

Adult T cell leukemia (ATL) is an aggressive T cell malignancy caused by human T cell leukemia virus type 1 (HTLV-1) and has a poor prognosis. We analyzed the cytotoxic effects of various nucleoside analog reverse transcriptase inhibitors (NRTIs) for HIV-1 on ATL cells and found that abacavir potently and selectively kills ATL cells. Although NRTIs have minimal genotoxicities on host cells, the therapeutic concentration of abacavir induced numerous DNA double-strand breaks (DSBs) in the chromosomal DNA of ATL cells. DSBs persisted over time in ATL cells but not in other cell lines, suggesting impaired DNA repair. We found that the reduced expression of tyrosyl-DNA phosphodiesterase 1 (TDP1), a repair enzyme, is attributable to the cytotoxic effect of abacavir on ATL cells. We also showed that TDP1 removes abacavir from DNA ends in vitro. These results suggest a model in which ATL cells with reduced TDP1 expression are unable to excise abacavir incorporated into genomic DNA, leading to irreparable DSBs. On the basis of the above mechanism, we propose abacavir as a promising chemotherapeutic agent for ATL.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。